Dublin, Jan. 07, 2025 (GLOBE NEWSWIRE) -- The "Cell & Gene Therapy Cold Chain Logistics Market Report 2024-2034" report has been added to ResearchAndMarkets.com's offering.

Overall world revenue for Cell and Gene Therapy Cold Chain Logistics Market will surpass US$1,800 million in 2024

This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

High Cancer Prevalence is Propelling the Adoption of Cell and Gene Therapies

The global incidence of cancer has been rising steadily over the past decade, significantly influencing the adoption of advanced treatments like cell and gene therapies. This increase includes various cancers such as lymphoma, leukemia, myeloma, and melanoma, which affect critical bodily systems including the lymphatic system, lymph nodes, bone marrow, and blood cells. PAHO/WHO reported that in 2023, there were around 20 million new cancer cases.

Projections indicate a notable increase in the global cancer burden, with over 28 million new cases expected by 2040. In the U.S., Non-Hodgkin lymphoma alone accounts for more than 4% of all cancer cases, making it one of the most prevalent types. These statistics underscore the urgent need for innovative treatments. Cell and gene therapies, which have shown remarkable success and received regulatory approval, are increasingly seen as vital to addressing the unmet medical needs of cancer patients worldwide.

Inadequate Infrastructure for Cold Chain Logistics in Developing Nations Likely to Challenge Industry Growth

Access to cell and gene therapies in developing and remote regions is significantly restricted by inadequate cold chain logistics infrastructure. The reliability of refrigeration is often compromised by inconsistent power supplies, leading to a heightened risk of product spoilage. Transportation infrastructure in these regions also poses a major challenge, complicating the timely delivery of therapies and resulting in delays. Overcoming these logistical barriers requires strategic partnerships with local logistics providers, such as Riders for Health in Africa, to ensure effective distribution networks.

Furthermore, the shortage of trained personnel in cold chain management exacerbates these issues, emphasizing the need for specialized training programs. Collaborations between global organizations like the WHO and local authorities are essential to enhancing cold chain logistics capabilities. Such partnerships can significantly improve the infrastructure needed to support the widespread availability of cell and gene therapies, ultimately expanding access to these critical treatments in underserved regions.

Key Questions Answered

• How is the cell and gene therapy cold chain logistics market evolving?
• What is driving and restraining the cell and gene therapy cold chain logistics market?
• How will each cell and gene therapy cold chain logistics submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
• How will the market shares for each cell and gene therapy cold chain logistics submarket develop from 2024 to 2034?
• What will be the main driver for the overall market from 2024 to 2034?
• Will leading cell and gene therapy cold chain logistics markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
• Who are the leading players and what are their prospects over the forecast period?
• What are the cell and gene therapy cold chain logistics projects for these leading companies?
• How will the industry evolve during the period between 2024 and 2034? What are the implications of cell and gene therapy cold chain logistics projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the cell and gene therapy cold chain logistics market?
• Where is the cell and gene therapy cold chain logistics market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

Forecasts to 2034 and other analyses reveal commercial prospects

• In addition to revenue forecasting to 2034, the new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), and recent developments.

Cell & Gene Therapy Cold Chain Logistics Market Dynamics

Market Driving Factors

• Advancements in Storage and Transportation of Biologics
• Increasing Adoption of Gene and Cell Therapies
• High Prevalence of Cancer and Genetic Disorders
• Increasing Strategic Initiatives Among Market Players

Market Restraining Factors

• High Cost of Cell and Gene Therapy Storage and Transportation
• Absence of Adequate Infrastructure for Cold Chain Logistics in Developing Nations

Market Opportunities

• Strong Clinical Pipeline and Increasing Approval for Cell and Gene Therapy Products
• Lucrative Opportunities in Developing Countries
• Stringent Government Regulations for Cell & Gene Therapy
• Favourable Initiatives and Programs for Easier Access to Cell and Gene Therapy

Regulatory Framework

Emerging Markets and Megatrends

Porter's Five Forces Analysis

PEST Analysis

Leading companies profiled in the report

• A.P. Moller - Maersk
• Arvato SE
• Atelerix Ltd.
• BioLife Solutions Inc.
• BioStor Sytems Inc.
• Cardinal Health
• Catalent Inc.
• Cencora, Inc.
• CryoPort Inc.
• DHL
• FedEx
• Marken (a UPS Company)
• MasterControl Solutions, Inc.
• Modality Solutions
• NMDP BioTherapies
• Nordic Cold Chain Solutions
• sedApta s.r.l.
• Polar Express Transportation
• Thermo Fisher Scientific Inc.
• TrakCel
• Yourway

Segments Covered in the Report

Component

• Cryogenic Shippers
• Cryogenic Storage Freezers
• Ultra-Low Freezers
• Cold Chain Management Systems
• Shipment and Storage Medium
• Cryogenic Packout Kits
• Others

Services

• Transportation
• Storage
• Packaging

Mode of Transport

• Air Transport
• Ground Transport
• Water Transport

Holding Temperature Range

• Cryogenic
• Refrigerated
• Ambient
• Others

End-users

• Biopharmaceutical and Biotechnology Companies
• Academic & Research Institutes
• Others

North America

• U.S.
• Canada

Europe

• Germany
• UK
• France
• Italy
• Spain
• Russia
• Switzerland
• Belgium
• Rest of Europe

Asia Pacific

• Japan
• China
• India
• Australia
• South Korea
• Singapore
• Malaysia
• Thailand
• Rest of Asia Pacific

Latin America

• Brazil
• Mexico
• Argentina
• Rest of Latin America

MEA

• GCC
• South Africa
• Rest of MEA

or more information about this report visit https://www.researchandmarkets.com/r/akdd5s

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.